A Myth

PureTech Ventures' John LaMattina this week says "there has never really been 'low-hanging fruit' in pharma R&D." Writing in Forbes, the former president of R&D at Pfizer says "the fact of the matter is that drug discovery has always been hard and that there have been spectacular failures over the years in pursuit of what its retrospectively viewed as 'low-hanging fruit,'" or easily attainable targets. "For decades, the fruit has always been hard to reach.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.